Immunitybio Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Immunitybio
IBRX Stock  USD 2.08  0.06  2.97%   
Immunitybio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Immunitybio's valuation are provided below:
Gross Profit
82.2 M
Market Capitalization
2 B
Enterprise Value Revenue
27.5461
Revenue
82.6 M
Earnings Share
(0.41)
We have found one hundred twenty available fundamental trends for Immunitybio, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Immunitybio regular market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 3.7 B in 2026. Enterprise Value is likely to rise to about 3.9 B in 2026

Immunitybio Total Revenue

17.8 Million

Check Immunitybio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunitybio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 10.1 M, Interest Expense of 159 M or Total Revenue of 17.8 M, as well as many indicators such as Price To Sales Ratio of 132, Dividend Yield of 0.0 or Days Sales Outstanding of 71.75. Immunitybio financial statements analysis is a perfect complement when working with Immunitybio Valuation or Volatility modules.
  
Build AI portfolio with Immunitybio Stock
Check out the analysis of Immunitybio Correlation against competitors.
For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.

Immunitybio Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets299.1 M440.4 M235.8 M
Slightly volatile
Short and Long Term Debt Total608.8 M579.8 M241.9 M
Slightly volatile
Total Current Liabilities104.2 M63.2 M77.6 M
Slightly volatile
Property Plant And Equipment Net205.8 M196 M82.7 M
Slightly volatile
Current Deferred Revenue85.5 K90 K251.1 K
Slightly volatile
Accounts Payable7.2 M7.7 M5.8 M
Slightly volatile
Cash94.3 M164.9 M75.9 M
Slightly volatile
Non Current Assets Total124.4 M228.1 M100.8 M
Slightly volatile
Cash And Short Term Investments159.8 M172.3 M122.1 M
Slightly volatile
Net Receivables2.7 M3.1 M2.2 M
Slightly volatile
Common Stock Total Equity50.7 K48.3 K19.4 K
Slightly volatile
Common Stock Shares Outstanding426.9 M805.5 M402.2 M
Slightly volatile
Liabilities And Stockholders Equity299.1 M440.4 M235.8 M
Slightly volatile
Non Current Liabilities Total985.5 M938.5 M280.2 M
Slightly volatile
Other Current Assets28.8 M27.4 M10.7 M
Slightly volatile
Other Stockholder Equity3.5 B3.3 B1.2 B
Slightly volatile
Total Liabilities1.1 B1 B354.5 M
Slightly volatile
Property Plant And Equipment Gross326.1 M310.6 M113.1 M
Slightly volatile
Total Current Assets174.7 M212.3 M135 M
Slightly volatile
Short Term Debt8.2 M8.6 M46.1 M
Slightly volatile
Intangible Assets19.2 M18.3 M8.1 M
Slightly volatile
Common Stock102.6 K97.8 K30.9 K
Slightly volatile
Other Assets8 M7.6 M2.9 M
Slightly volatile
Short Term Investments5.5 M5.7 M77.5 M
Slightly volatile
Capital Surpluse1.3 B2.2 B1.1 B
Slightly volatile
Property Plant Equipment173.5 M165.2 M67.7 M
Slightly volatile
Other Liabilities26.6 M25.3 M11.8 M
Slightly volatile
Long Term Debt428 M531.2 M320.5 M
Slightly volatile
Capital Lease Obligations43.9 M48.6 M29.6 M
Slightly volatile
Capital Stock59.8 K97.8 K47.6 K
Slightly volatile
Non Current Liabilities Other190.3 M327.8 M87.1 M
Slightly volatile
Deferred Long Term Liabilities129.6 K145.8 K159.1 K
Slightly volatile
Short and Long Term Debt402.1 M496.7 M340.3 M
Slightly volatile
Good Will728 K819 K893.9 K
Slightly volatile

Immunitybio Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization10.1 M20.2 M8.3 M
Slightly volatile
Total Revenue17.8 M17 M3.3 M
Slightly volatile
Other Operating Expenses207.5 M412.8 M170.1 M
Slightly volatile
Research Development229.6 M218.7 M96.3 M
Slightly volatile
Total Operating Expenses433.4 M412.8 M181.7 M
Slightly volatile
Selling General Administrative98.8 M194.1 M76.3 M
Slightly volatile
Selling And Marketing Expenses34.3 M32.6 M15.1 M
Slightly volatile
Interest Income1.9 M2.2 M3.3 M
Slightly volatile
Reconciled Depreciation17.6 M20.2 M15.3 M
Slightly volatile
Non Recurring544.8 K612.9 K669 K
Slightly volatile

Immunitybio Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation34.2 M31 M34.1 M
Pretty Stable
Begin Period Cash Flow320.9 M305.7 M97.2 M
Slightly volatile
Depreciation12.1 M20.2 M9.7 M
Slightly volatile
Capital Expenditures7.5 M7.9 M13.4 M
Slightly volatile
End Period Cash Flow100 M165.5 M79.9 M
Slightly volatile
Dividends Paid673 K708.4 K21.5 M
Pretty Stable
Issuance Of Capital Stock112.5 M128.1 M66.1 M
Slightly volatile
Cash Flows Other Operating2 M3.3 M1.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio13213919.5 K
Slightly volatile
Days Sales Outstanding71.7575.527.3 K
Very volatile
Stock Based Compensation To Revenue2.552.69484
Slightly volatile
Capex To Depreciation0.340.351.6044
Very volatile
EV To Sales18019019.7 K
Slightly volatile
Inventory Turnover0.740.830.9023
Slightly volatile
Days Of Inventory On Hand318358391
Slightly volatile
Sales General And Administrative To Revenue802544589
Slightly volatile
Research And Ddevelopement To Revenue11.0311.61271
Pretty Stable
Capex To Revenue0.40.42101
Very volatile
Cash Per Share0.30.190.2957
Slightly volatile
Income Quality0.510.850.5883
Slightly volatile
Intangibles To Total Assets0.06990.04780.1242
Slightly volatile
Current Ratio3.673.867.2587
Pretty Stable
Receivables Turnover5.255.02.1026
Slightly volatile
Capex Per Share0.00840.00890.0362
Slightly volatile
Revenue Per Share0.020.0190.0046
Slightly volatile
Interest Debt Per Share1.281.220.5936
Slightly volatile
Debt To Assets1.951.860.911
Slightly volatile
Operating Cycle71.7575.527.4 K
Very volatile
Ebt Per Ebit0.871.081.0346
Slightly volatile
Quick Ratio3.513.697.2273
Pretty Stable
Net Income Per E B T1.11.151.0132
Slightly volatile
Cash Ratio6.03.04.3877
Pretty Stable
Days Of Inventory Outstanding318358391
Slightly volatile
Days Of Sales Outstanding71.7575.527.3 K
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.261.171.1317
Pretty Stable
Fixed Asset Turnover0.09450.099511.0603
Slightly volatile
Debt Ratio1.951.860.911
Slightly volatile
Price Sales Ratio13213919.5 K
Slightly volatile
Asset Turnover0.03280.04430.0759
Slightly volatile

Immunitybio Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.7 B2.9 B5.1 B
Slightly volatile
Enterprise Value3.9 B3.5 B5.2 B
Slightly volatile

Immunitybio Fundamental Market Drivers

Immunitybio Upcoming Events

14th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Immunitybio Financial Statements

Immunitybio investors use historical fundamental indicators, such as Immunitybio's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunitybio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue90 K85.5 K
Total Revenue17 M17.8 M
Cost Of Revenue20.2 M10.4 M
Stock Based Compensation To Revenue 2.69  2.55 
Sales General And Administrative To Revenue 543.71  802.07 
Research And Ddevelopement To Revenue 11.61  11.03 
Capex To Revenue 0.42  0.40 
Revenue Per Share 0.02  0.02 
Ebit Per Revenue(21.01)(22.06)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY